- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00822094
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.
The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study is a randomized, open-label, parallel-arm, fixed-dose, standard therapy controlled Phase IIB trial. Study enrollment duration is expected to be approximately 12-18 months. On entry, patients are randomized to receive either CPX-351 or intensive first salvage treatment.
Patients are stratified to balance the likelihood of obtaining a CR and the duration of CR between the two arms.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Vancouver General Hospital/ British Columbia Cancer Agency
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 049
- Cancer Care Manitoba
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85724
- Arizona Cancer Center
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Cedars Sinai Medical Center
-
Los Angeles, California, Estados Unidos, 90024
- UCLA
-
Sacramento, California, Estados Unidos, 95817
- UC Davis Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Cancer Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush University Medical Center
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Medical Center Section of Hematology/Oncology
-
-
Indiana
-
Beech Grove, Indiana, Estados Unidos, 46107
- St. Francis Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- University of Louisville Brown Cancer Center
-
-
Maine
-
Waterville, Maine, Estados Unidos, 04901
- Maine General Medical Center Harold Alfond Center for Cancer Care
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21231
- Johns Hopkins University
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos, 63101
- St. Louis University Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- The Cancer Center, Hackensack University Medical Center
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- North Shore LIJ Center for Advanced Medicine Monter Cancer Center
-
New York, New York, Estados Unidos, 10021
- Weil Cornell Medical Center
-
New York, New York, Estados Unidos, 10595
- New York Medical College
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Blumenthal Cancer Center/Mecklenburg Medical Group
-
Durham, North Carolina, Estados Unidos, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos
- Jewish Hospital of Cincinatti
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18105
- Oncology and Hematology at Lehigh Valley
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Western Pennsylvania Hospital
-
-
Texas
-
Galveston, Texas, Estados Unidos, 77555
- UTMB Comprehensive Cancer Center
-
Houston, Texas, Estados Unidos, 77030
- M.D. Anderson Cancer Center
-
Lubbock, Texas, Estados Unidos, 79410
- Joe Arrington Cancer Center
-
Lubbock, Texas, Estados Unidos, 79415
- Texas Tech University Health Sciences Center
-
San Antonio, Texas, Estados Unidos, 78229
- Cancer Therapy and Research Center at The University of TX Health Science Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84143
- Intermountain LDS Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
-
-
-
Lille Cedex, Francia, 59037
- Service des Maladies du Sang CHU de Lille, Hopital Claude Huriez
-
Pessac, Francia, 33604
- Service des Maladies du Sang Hopital Haut-Leveque
-
Toulouse Cedex 09, Francia, 31059
- Service d'Hématologie CHU Toulouse-Hôpital Purpan
-
Vandoeuvre les Nancy Cedex, Francia, 54511
- Service d'Hématologie et Médecine Interne CHU de Nancy-Hôpital de Brabois
-
-
-
-
-
Gdansk, Polonia, 80-952
- Klinika Hematologii i Transplantologii
-
Lodz, Polonia, 93-510
- Wojewodzki Szpital Specjalistyczny im. M. Kopernika
-
Opole, Polonia, 45-372
- Oddział Hematologii
-
Warszawa, Polonia, 02-776
- Instytut Hematologii i Transfuzjologii
-
Wroclaw, Polonia, 50-367
- Akademia Medyczna we Wroclawlu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Ability to understand and voluntarily sign an informed consent form
- Age ≥18 and ≤65 years at the time of relapse
- Pathological confirmation of relapsed AML after initial CR of >1 month duration
- Eastern Cooperative Oncology Group (ECOG) performance status 0- 2
- Able to adhere to the study visit schedule and other protocol requirements
Laboratory values fulfilling the following:
- Serum creatinine < 2.0 mg/dL
- Serum total bilirubin < 2.0 mg/dL
- Serum alanine aminotransferase or aspartate aminotransferase <3xULN Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.
- Cardiac ejection fraction > 50% by echocardiography or MUGA scan
- All men and women must agree to practice effective contraception during the study period and for 3 months afterward if not otherwise documented to be infertile.
Exclusion Criteria:
- Patients with active second malignancies are excluded. Patients with second malignancies in remission may be eligible if there is no clinical evidence of active disease, documented by imaging, with tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible. In all cases, the second malignancy and its non-chemotherapy treatment must not interfere with the investigators ability to assess the safety or efficacy of the study treatment
- Patients with acute promyelocytic leukemia [t(15;17)]
- Total lifetime anthracycline exposure exceeding the equivalent of 368 mg/m2 of daunorubicin (or equivalent) prior to start of study therapy
- Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent
- Administration of any antineoplastic therapy within 4 weeks of therapy; intended to treat first relapse. In the event of rapidly proliferative disease use of hydroxyurea is permitted until 24 hours before the start of study treatment
- Clinical evidence of active CNS leukemia
- Patients with history of and/or current evidence of myocardial impairment (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in New York Heart Association Class III or IV staging
- Active and uncontrolled infection. Patients with a bacterial infection receiving treatment with antibiotics may be entered into the study if they are afebrile and hemodynamically stable for >72 hrs.
- Current evidence of invasive fungal infection (blood or tissue culture); active hepatitis C infection or known HIV infection
- Hypersensitivity to cytarabine, daunorubicin or liposomal products
- History of Wilson's disease or other copper-related disorder
- Patients with a history of severe toxicity related to receiving conventional dose cytarabine in first line treatment (approximately 100mg/m2/d for <7 days) are excluded. Patients who experienced unacceptable toxicities while receiving high dose cytarabine (approximately 3000mg/m2 for 6 doses) will not be treated again with the same regimen, but could be randomized to treatment with conventional dose cytarabine regimens where the risk of major toxicity is less.
- Woman who are pregnant or breast feeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: CPX-351 (Arm A)
First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
|
|
Comparador activo: Salvage Therapy (Arm B)
First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proportion of Subjects Surviving at 1 Year
Periodo de tiempo: Up to 1 year from randomization
|
The proportion of subjects surviving at 1 year was evaluated separately for each arm by the number of subjects alive at 1 year divided by the total number of subjects.
|
Up to 1 year from randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Complete Remission Rate
Periodo de tiempo: Following 1st induction, following 2nd induction if applicable
|
Following 1st induction, following 2nd induction if applicable
|
|
Event Free Survival
Periodo de tiempo: Up to 1 year from randomization
|
Progression EFS median
|
Up to 1 year from randomization
|
Remission Duration
Periodo de tiempo: Following achievement of CR and up to 1 year from randomization
|
Remission duration was measured from the time the criteria for CR were first met until the first date that disease relapse was objectively documented or until subject death.
|
Following achievement of CR and up to 1 year from randomization
|
Rate of Aplasia
Periodo de tiempo: Up to 1 year from randomization
|
Patients with Aplasia During Study
|
Up to 1 year from randomization
|
Rate of Stem Cell Transplant
Periodo de tiempo: Up to 1 year from randomization
|
Number of patients transferred for stem cell transplant
|
Up to 1 year from randomization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jonathan Kolitz, MD, North Shore University Hospital
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CLTR0308-205
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre CPX-351
-
French Innovative Leukemia OrganisationAcute Leukemia French Association; French Intergroup of Myeloproliferative syndromesReclutamientoLeucemia mieloide aguda | Síndrome mieloproliferativoFrancia
-
Case Comprehensive Cancer CenterActivo, no reclutandoSíndromes mielodisplásicos | Leucemia mieloide aguda refractaria | Leucemia mielomonocítica aguda recidivanteEstados Unidos
-
Jazz PharmaceuticalsIqvia Pty LtdTerminado
-
Groupe Francophone des MyelodysplasiesTerminado
-
Jazz PharmaceuticalsTerminadoLeucemia mieloide aguda relacionada con la terapia | Leucemia mieloide aguda con cambios relacionados con mielodisplasiaEstados Unidos
-
Jazz PharmaceuticalsAdvice Pharma S.r.l.ReclutamientoLeucemia mieloide aguda (LMA) | Leucemia mieloide aguda relacionada con la terapia | Leucemia mieloide aguda con cambios relacionados con mielodisplasiaItalia
-
Yale UniversityRetirado
-
Jazz PharmaceuticalsTerminadoLeucemia mieloide aguda | Síndromes mielodisplásicos | Leucemia linfoblástica aguda | Leucemia linfocítica aguda | Malignidad hematológicaEstados Unidos, Canadá
-
Jazz PharmaceuticalsTerminadoLeucemia mieloide aguda (LMA) | Leucemia linfoblástica aguda (LLA) | Síndrome mielodisplásico (SMD)Estados Unidos
-
Jazz PharmaceuticalsAprobado para la comercializaciónLMA secundariaEstados Unidos